You are here

Home » Content

Uterin Papiller Seröz Karsinom: 10 Olgunun Analizi

Uterine Papillary Serous Carcinoma: Analysis of 10 Cases

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2001

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objective: To establish the prognosis and effect of full surgicopathological staging followed by radiotherapy in patients with uterine papillary serous carcinoma (UPSC). Study Design: Between January 1992 and September 2000, fourteen patients with UPSC were treated. All medical records were reviewed. The 2 -year acturial disease specific survival rate was calculated by using Life -Table. Wilcoxon (Gehan) statistic was used in comparing prognostic factors related with acturial disease specific survival. Results: The median duration of follow-up was 16 months (range, 4-22 months).The 2-year acturial disease specific survival rate was found to be 49.3%. The median overall survival was 14.8 months. Wilcoxon (Gehan) statistic revealed that patients with elevated CA-125 levels at diagnosis did significantly better than patients with initial CA-125 levels at normal ranges (p=0.021). Conclusion: Our findings suggest that postoperative treatment with whole pelvic irradiation combined with high dose rate brachytherapy appears to be inadequate in the adjuvant therapy of patients with UPSC.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Uterin papiller seröz karsinom olgularında cerrahi evrelendirmeyi takiben uygulanan radyoterapinin etkinliğini ve hastalığın prognozunu belirlemek. Çalışma Şekli: Ocak 1992-Eylül 2000 tarihleri arasında uterin papiller seröz karsinom tanısı alan 10 olgu tedavi edildi. Tıbbi kayıtlar incelenerek hastalığa özgü iki yıllık sağ kalım oranı Yaşam Tablosu kullanılarak hesaplandı. Hastalığa özgü iki yıllık sağ kalıma etki eden prognostik faktörler Wilcoxon (Gehan) istatistiği ile belirlendi. Bulgular: Ortanca takip süresinin 16 ay olduğu bulundu (4-22 ay). Hastalığa özgü iki yıllık sağ kalım oranının %49.3 olduğu saptandı. Ortanca sağ kalım süresinin 14.8 ay olduğu belirlendi. Wilcoxon (Gehan) istatistiği, tanı sırasında yüksek CA-125 düzeyi saptanan olgulardaki sonuçların başlangıç CA-125 düzeyi normal sınırlarda olan olgulara göre daha iyi olduğunu ortaya koydu (p=0.021). Sonuç: Bizim bulgularımız, uterin papiller seröz karsinomu olan olgularda, postoperatif adjuvan tedavi olarak pelvik radyasyon ve brakiterap i kombinasyonunun yetersiz olduğuna işaret etmektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-uterin-papiller-seroz-karsinom-10-olgunun-analizi.pdf
  • 4
167-173
  • Turkish

REFERENCES

References: 

1. Gitsch G, Friedlander ML, Wain GV, Hacker NF. Uterine papillary serous carcinoma. A Clinical Study. Cancer 1995; 75: 2239-43.
2. Bristow RE. Endometrial cancer. Curr Opin Oncol 1999; 11: 388-93.
3. Dunton CJ, Baisara G, Mc Farland M, Hernandez E. Uterine papillary serous carcinoma: a review. Obstet Gynecol Surv 1991; 46: 97-102.
4. Bancher-Todesca D, Neunteufel W, Williams KE et al. Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma. Gynecol Oncol 1998; 71: 344-47.
5. FIGO Stages: 1988 Revision. Gynecol Oncol 1989; 35: 125-127.
6. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg
Pathol 1982; 6: 93-108.
7. Kurman RJ, Norris HJ. Endometrial carcinoma.in Kurman RJ (ed), Blaustein's Pathology of the female genital tract, New York, Springer Verlag, 1987, pp.338¬372.
8. Moll UM, Chalas E, Augeste M, Meaney D, Chumas J. Uterine papillary serous
carcinoma evolves via a p53-driven pathway. Hum Pathol 1996; 27: 1295-1300.
9. Miller B, Umpierre S, Tornos C, Burke T. Histologic characterization of uterine papillary serous adenocarcinoma. Gynecol Oncol 1995; 56: 425-9.
10. Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG e t al. Uterine papillary serous carcinoma: patterns of metastatic spread.Gynecol Oncol 1994; 54:
264-68.
11. Prat J, Oliva E, Lerma E, Vaquero M, Matias-Guiu X. Uterine papillary serous
adenocarcinoma. Cancer 1994; 74: 1778-1783.
12. Rosenberg P, Boeryd B, Simonsen E. A new agressive treatment approach to high-grade endometrial cancer of possible benefit to patients with Stage I uterine
papillary cancer. Gynecol Oncol 1993; 48: 32-37.
13. Chambers JT, Merino M, Kohorn EI, Peschel RE, Schwartz PE. Uterine papillary
serous carcinoma. Obstet Gynecol 1987; 69: 109-113.
14. Rosenberg P, Blom R, Hogberg T, Simonsen E. Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma. Gynecol Oncol 1993; 51: 311-5.
15. Ho TH, Lim TL, Tan HS. Uterine papillary serous carcinoma-the KK Hospital
experience. Ann Acad Med Singapore 1998; 27: 640-644.
16. Abramovich D, Markman M, Kennedy A, Webster K, Belinson J. Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma. J Cancer Res Clin Oncol 1999; 125: 697-8.
17. Nicklin JL, Copeland LJ. Endometrial papillary serous carcinoma: patterns of spread and treatment. Clin Obstet Gynecol 1996; 39: 686-95.
18. Levenback C, Burke TW, Silva E, Morris M, Gershenson DM, Kavagh JJ, et al. Uterine papillary serous carcinoma treated with cisplatin, doxorubicin and
cyclophosphamide (PAC). Gynecol Oncol 1992; 46: 317-321.
19. Price VF, Chambers SK, Carcangiu ML, Kohern EI, Schwartz PE, Chambers JT. Intravenous cisplatin, doxorubicin and cyclophosphamide in the treatment of
uterine papillary serous carcinoma. Gynecol Oncol 1993; 51: 383-389.
20. Sutton GP, Brill L, Michael H, Stehman FB, Ehrich CE. Malignant papillary lesions of the endometrium.Gynecol Oncol 1987; 27: 294-304.
21. Christman JE, Knapp SK, Hendrickson MR, Howes AE, Ballon SC. Therapeutic approaches to uterine papilary serous carcinoma: a preliminary report. Gynecol
Oncol 1987; 26: 228-235.
Uterine Papillary Serous Carcinoma: Analysis of 10 Cases
22. Gallion HH, Van Nageli JR, Powell DF, Donaldson ES, Higgins RV, Krysio RJ, et aL Stage I serous papillary carcinoma of the endometrium. Cancer 1989; 63: 2224¬2228.
23. Mallipeddi P, Knapp DS, Teng NN. Long-term survival with adjuvant whole abdominopelvic irradiation for uterine papillary serous carcinoma. Cancer 1993; 71: 3076-3081.
24. Frank AH, Tseng PC, Haffty BG, Papadopoulos DP, Kacinski BM, Dowling SW, et al. Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma. Cancer 1991; 68: 1516-1519.

Thank you for copying data from http://www.arastirmax.com